Table 2 p63 immunostaining and tumor phenotype

Urinary bladder cancer

all cancers

1038

13.4

5.9

9.1

71.7

pTa G2 low

116

0.0

0.0

2.6

97.4

<0.0001

pTa G2 high

106

0.0

0.9

8.5

90.6

pTaG3

132

9.8

6.1

15.2

68.9

pT≥2 G3

672

18.6

7.0

9.2

65.2

pT≥2 G3 sarcomatoid

18

44.4

11.1

5.6

38.9

0.0052 (vs >pT2G3)

pT≥2 G3 small cell ca.

18

88.9

5.6

5.6

0.0

<0.0001 (vs ≥pT2G3)

pN0

111

13.5

8.1

9.0

69.4

0.9138

pN+

71

15.5

5.6

8.5

70.4

Pancreatic adenocarcinoma

all cancers

422

84.4

5.7

3.1

6.9

pT1

12

91.7

0

0

8.3

0.2753

pT2

63

92.1

3.2

1.6

3.2

pT3

318

82.4

6.9

3.1

7.5

pT4

27

85.2

0

7.4

7.4

G1

12

100

0

0

0

0.3483

G2

295

82.7

7.1

3.1

7.1

G3

92

85.9

3.3

2.2

8.7

pN0

91

85.7

3.3

4.4

6.6

0.5777

pN+

329

83.9

6.4

2.7

7

pM0

334

83.2

6.3

3

7.5

0.515

pM1

87

88.5

3.4

3.4

4.6

R0

212

83.5

7.1

2.4

7.1

0.5384

R1

174

85.6

4.6

4

5.7

Endometrial cancer, endometrioid

all cancers

160

83.1

4.4

12.5

0.0

pT1

101

83.2

3.0

13.9

0.0

0.6733

pT2

23

87.0

4.3

8.7

0.0

pT3-4

33

78.8

9.1

12.1

0.0

pN0

43

83.7

4.7

11.6

0.0

0.3704

pN+

28

75.0

14.3

10.7

0.0

Ovarian cancers, serous

all cancers

374

91.7

5.1

2.4

0.8

pT1

29

93.1

3.4

3.4

0.0

0.2274

pT2

39

84.6

5.1

10.3

0.0

pT3

257

91.8

5.4

1.6

1.2

pN0

81

88.9

4.9

4.9

1.2

0.3673

pN+

166

91.0

6.6

1.2

1.2

Stomach cancer

all cancers

355

96.1

1.1

0.6

2.3

diffuse

85

97.6

2.4

0.0

0.0

0.1478

intestinal

79

97.5

0.0

0.0

2.5

mixed

56

94.6

1.8

0.0

3.6

pT1-2

57

96.5

0.0

1.8

1.8

0.3119

pT3

117

94.9

0.9

0.9

3.4

pT4

118

96.6

2.5

0.0

0.8

pN0

74

100.0

0.0

0.0

0.0

0.0208

pN1

62

93.5

1.6

3.2

1.6

pN2

55

92.7

0.0

0.0

7.3

pN3

101

96.0

3.0

0.0

1.0